核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究进展

摘要/Abstract

摘要： 慢性乙型肝炎作为由乙型肝炎病毒引发的一种全球性传染病,对人类生命健康构成严重威胁。随着核酸检测技术的改进,部分接受核苷(酸)类似物抗病毒治疗的患者,在治疗过程中出现“低病毒血症”。慢性乙型肝炎病毒血症增加疾病进展风险,肝癌和耐药性也会增加。低病毒血症已成为当前抗病毒治疗的一个重要且具有挑战性的领域。本文系统地阐明低病毒血症的发病机制、临床表现及其与疾病进展之间的关联,同时,对当前可用的治疗策略进行系统性回顾,以期为临床医生在面对低病毒血症患者时提供科学、实用的指导原则与治疗建议。

金燚, 沈泳利, 李佟. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究进展[J]. 肝脏, 2024, 29(8): 896-899.

/ 推荐

参考文献 41

[1]	Sneller L, Lin C, Price A, et al. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects[J]. Microorganisms, 2024, 12(3):599.
[2]	Fernandes DA Silva C, Keeshan A, COOPER C. Hepatitis B virus genotypes influence clinical outcomes:A review[J]. Can Liver J, 2023, 6(3):347-352.
[3]	Foko S. Dynamical analysis of a general delayed HBV infection model with capsids and adaptive immune response in presence of exposed infected hepatocytes[J]. J Math Biol, 2024, 88(6):75.
[4]	Hou JL, Zhao W, Lee C, et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries[J]. Clin Gastroenterol Hepatol, 2020, 18(2):457-467,e421.
[5]	Alshuwaykh O, Daugherty T, Cheung A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy[J]. Hepatol Commun, 2022, 6(11):3052-3061.
[6]	Yim HJ, Kang SH, Jung YK, et al. Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy[J]. Cancers (Basel), 2024, 16(5):887.
[7]	Zhang Q, Peng H, Liu X, et al. Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease[J]. J Clin Transl Hepatol, 2021, 9(6):850-859.
[8]	Varghese N, Majeed A, Nyalakonda S, et al. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J]. Cancers (Basel), 2024, 16(4):777.
[9]	Shin SK, Yim HJ, Kim JH, et al. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis[J]. Gut Liver, 2021, 15(3):430-439.
[10]	Suzuki F, Suzuki Y, Karino Y, et al. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients:a phase 4, prospective study[J]. BMC Gastroenterol, 2021, 21(1):489.
[11]	Ignat MD, Balta AAS, Barbu RE, et al. Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future[J]. J Clin Med, 2024, 13(7):2055.
[12]	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398.
[13]	Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4):1560-1599.
[14]	Wang X, Cai D, Juan Z. SAT447 - Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide[J]. Chongqing Med Univ, Affiliated Hosp 2, Infect Dis, Chongqing, Peoples R China, 2022, Vol.77(Suppl 1):S878.
[15]	Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV:Stopping NUCs, adding interferon or new drug development?[J]. J Hepatol, 2022, 76(6):1249-1262.
[16]	Leowattana W, Leowattana T. Chronic hepatitis B:New potential therapeutic drugs target[J]. World J Virol, 2022, 11(1):57-72.
[17]	Hu JL, Huang AL. Dynamics of Hepatitis B Virus Covalently Closed Circular DNA:A Mini-Review[J]. Microorganisms, 2023, 11(3):600.
[18]	王雷婕, 顾智强, 许梓萌,等. 核苷(酸)类药物经治慢性乙型肝炎患者低病毒血症发生的可能机制[J]. 中华肝脏病杂志, 2021, 29(12):1151-1155.
[19]	杨瑞锋, 陈红松, 鲁凤民. 当今慢性乙型肝炎治疗实践对HBV核酸检测方法的新需求[J]. 中国临床新医学, 2021, 14(1):1-7.
[20]	王贵强,王福生,庄辉,等. 慢性乙型肝炎防治指南(2019年版)[J]. 中国病毒病杂志, 2020, 10(1):1-25.
[21]	Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years[J]. Aliment Pharmacol Ther, 2012, 35(11):1326-1335.
[22]	Sun Y, Wu X, Zhou J, et al. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11):2582-2591,e2586.
[23]	Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1):65-73.
[24]	Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2):335-343.
[25]	Kim TS, Sinn DH, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia[J]. J Gastroenterol Hepatol, 2019, 34(11):2028-2035.
[26]	Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020, 26(3):364-375.
[27]	Park JH, Ahn SJ, Cho HJ, et al. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B[J]. J Med Virol, 2016, 88(2):252-259.
[28]	Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7):1578-1589.
[29]	Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4):1058-1066.
[30]	Shin JW, Jung SW, Lee SB, et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir[J]. Am J Gastroenterol, 2018, 113(7):998-1008.
[31]	Yuen MF, Schiefke I, Yoon JH, et al. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection[J]. Hepatology, 2020, 72(1):19-31.
[32]	Nakanishi A, Okumura H, Hashita T, et al. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2[J]. Viruses, 2022, 14(11):2468.
[33]	Philips CA, Ahamed R, Abduljaleel JK, et al. Critical Updates on Chronic Hepatitis B Virus Infection in 2021[J]. Cureus, 2021, 13(10):e19152.
[34]	Berke JM, Dehertogh P, Vergauwen K, et al. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus[J]. Antimicrob Agents Chemother, 2017, 61(8):e00560-17.
[35]	Klumpp K, Lam AM, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J]. Proc Natl Acad Sci U S A, 2015, 112(49):15196-15201.
[36]	Prifti GM, Moianos D, Giannakopoulou E, et al. Recent Advances in Hepatitis B Treatment[J]. Pharmaceuticals (Basel), 2021, 14(5):417.
[37]	Ide M, Tabata N, Yonemura Y, et al. Hepatitis B virus evades the immune system by suppressing the NF-κB signaling pathway with DENND2A[J]. Microbiol Spectr, 2024, 12(3):e0378523.
[38]	Soleiman-meigooni S, Yarahmadi A, Kheirkhah AH, et al. Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review[J]. Front Immunol, 2024, 15:1363996.
[39]	Wang J, Chen R, Zhang R, et al. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication[J]. Theranostics, 2017, 7(12):3090-3105.
[40]	Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B:A pilot study[J]. J Hepatol, 2019, 71(5):900-907.
[41]	Shin YW, Cho DH, Song GW, et al. A New ELISA to Overcome the Pitfalls in Quantification of Recombinant Human Monoclonal Anti-HBs, GC1102, by Commercial Immunoassays[J]. Biol Proced Online, 2018, 20:18.

核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘世超, 黄嘉敏, 伍婷, 黄国仪, 董京科, 王方, 何清. 新型标记物HBcrAg预测CHB功能性治愈及其临床价值的研究进展[J]. 肝脏, 2024, 29(9): 1024-1028.
[2]	何谱, 刘文宗. 抗病毒治疗慢性乙型肝炎患者发生低病毒血症的危险因素[J]. 肝脏, 2024, 29(9): 1105-1108.
[3]	杨丽, 孙君. 慢性乙型肝炎患者HBV DNA载量与血清miR-122、miR-223水平的关系[J]. 肝脏, 2024, 29(8): 947-951.
[4]	孔维菊, 任传路, 周昱岐, 李竞争, 何清, 袁俊菲. 血清PIVKA-Ⅱ在HBV相关肝癌患者中的表达及其与肝功能的相关性[J]. 肝脏, 2024, 29(7): 794-797.
[5]	刘艳午, 田丹, 宋晶晶. 超声剪切波弹性成像结合血浆NRG4水平评估慢性乙型肝炎肝纤维化程度的价值[J]. 肝脏, 2024, 29(7): 825-829.
[6]	刘明, 郭艳, 陈文婷, 况雪梅, 李世炼, 揭丽, 夏杰, 毛青, 朱研. HBeAg阳性妊娠慢性HBV携带者母婴阻断停药后肝炎活动的危险因素研究[J]. 肝脏, 2024, 29(7): 834-839.
[7]	谢艳迪, 张昕怡, 封波. HBeAg阴性慢性HBV感染期患者的临床治愈及影响因素[J]. 肝脏, 2024, 29(6): 631-634.
[8]	郝坤艳, 陈宇星, 汪文洋, 朱浩, 沈敏, 阳文新, 于乐成. 聚乙二醇干扰素对核苷(酸)类似物经治与未治的HBsAg低水平慢性乙型肝炎患者48周疗效比较[J]. 肝脏, 2024, 29(6): 635-640.
[9]	王春菊, 高嘉敏, 李丽容. 慢性乙型肝炎患者甲状腺激素水平与HBsAg水平及病情严重程度的相关性分析[J]. 肝脏, 2024, 29(6): 641-644.
[10]	宋舒瑛, 谢青, 姜绍文. 乙型肝炎治愈的临床研究进展[J]. 肝脏, 2024, 29(6): 725-730.
[11]	曾阿娟, 李磊, 丁惠国. 丙酚替诺福韦治疗失代偿期乙型肝炎肝硬化应答不佳/低病毒血症的疗效及安全性[J]. 肝脏, 2024, 29(5): 504-507.
[12]	汪蕾, 陈晨, 华喜梅, 胡丰芬. 血清β-arrestin 2、HIF-1a及CA125联合预测慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2024, 29(5): 521-525.
[13]	李明慧, 王麟, 鲁凤民. 慢性乙型肝炎常见PC/BCP突变的可能致病机制[J]. 肝脏, 2024, 29(4): 371-373.
[14]	刘韵, 徐云, 韩亮, 钱艺, 谭碧波. 实时组织弹性成像评估慢性乙型肝炎患者食管静脉曲张的研究[J]. 肝脏, 2024, 29(4): 423-428.
[15]	蔡云, 赵凯, 潘良, 周鑫. IL-21参与HBeAg阳性慢性乙型肝炎的免疫发病机制的研究[J]. 肝脏, 2024, 29(4): 436-439.